UiO-66(Zr) as drug delivery system for non-steroidal anti-inflammatory drugs

Vista sencilla de ítem
dc.contributor.authorSalazar, Javier
dc.contributor.authorHidalgo-Rosa, Yoan
dc.contributor.authorBurboa, Pia C.
dc.contributor.authorEscalona, Néstor
dc.contributor.authorLeiva, Angel
dc.contributor.authorZarate, Ximena
dc.contributor.authorSchott, Eduardo
dc.date.accessioned2024-11-21T15:10:05Z
dc.date.available2024-11-21T15:10:05Z
dc.date.issued2024-06-06
dc.description.abstractThe toxicity for the human body of non-steroidal anti-inflammatory drugs (NSAIDs) overdoses is a consequence of their low water solubility, high doses, and facile accessibility to the population. New drug delivery systems (DDS) are necessary to overcome the bioavailability and toxicity related to NSAIDs. In this context, UiO-66(Zr) metal-organic framework (MOF) shows high porosity, stability, and load capacity, thus being a promising DDS. However, the adsorption and release capability for different NSAIDs is scarcely described. In this work, the biocompatible UiO-66(Zr) MOF was used to study the adsorption and release conditions of ibuprofen, naproxen, and diclofenac using a theoretical and experimental approximation. DFT results showed that the MOF-drug interaction was due to an intermolecular hydrogen bond between protons of the groups in the defect sites, (μ3 − OH, and − OH2) and a lone pair of oxygen carboxyl functional group of the NSAIDs. Also, the experimental results suggest that the solvent where the drug is dissolved affects the adsorption process. The adsorption kinetics are similar between the drugs, but the maximum load capacity differs for each drug. The release kinetics assay showed a solvent dependence kinetics whose maximum liberation capacity is affected by the interaction between the drug and the material. Finally, the biological assays show that none of the systems studied are cytotoxic for HMVEC. Additionally, the wound healing assay suggests that the UiO-66(Zr) material has potential application on the wound healing process. However, further studies should be done.
dc.identifier.citationJournal of Controlled Release, Vol 370, (2024) p. 392-404.
dc.identifier.doihttps://doi.org/10.1016/j.jconrel.2024.04.035
dc.identifier.issn0168-3659
dc.identifier.issne1873-4995
dc.identifier.orcidhttps://orcid.org/0000-0002-1391-435X
dc.identifier.urihttp://hdl.handle.net/20.500.12254/3883
dc.language.isoen
dc.publisherElsevier
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subjectUiO-66@NSAID
dc.subjectDrug release
dc.subjectDrug delivery systems
dc.subjectMolecular modelling
dc.titleUiO-66(Zr) as drug delivery system for non-steroidal anti-inflammatory drugs
dc.typeArticle
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Referencia Hidalgo-Rosa.pdf
Tamaño:
74.95 KB
Formato:
Adobe Portable Document Format
Descripción:
Texto referencial
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
347 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Artículos de Revistas